ADC Therapeutics (ADCT) Gross Margin (2023 - 2026)
ADC Therapeutics' (ADCT) quarterly Gross Margin came in at 36.56% in Q1 2026, up 14762.0% year-on-year from N/an in Q1 2025, and up 13.77% quarter-over-quarter from 32.14% in Q3 2025.
ADC Therapeutics (ADCT) Gross Margin (2023 - 2026) Analysis & Trends
ADC Therapeutics has disclosed Gross Margin across 4 years of filings, most recently posting 36.56% for Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 79.04% |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 86.85% |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | ADC Therapeutics | 167.24 Mn | -63.76 Mn | 7.33 Mn | 36.56% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 36.56% |
| Sep 30, 2025 | 32.14% |
| Jun 30, 2025 | 46.14% |
| Mar 31, 2025 | -111.06% |
| Sep 30, 2024 | 40.76% |
| Jun 30, 2024 | 37.16% |
| Mar 31, 2024 | 36.91% |
| Sep 30, 2023 | 5.26% |
| Jun 30, 2023 | 25.03% |